CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

Phase 2Not Yet RecruitingNCT07576699

Cellenkos, Inc.12 enrolled

Overview

The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)

This clinical trial will be conducted in two parts where the first part of Phase 1b will determine the safety and tolerability of CK0802 in patients with steroid refractory GVHD and the second part of Phase 2a will examine the preliminary efficacy of CK0802 in patients with steroid refractory GVHD

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Steroid Refractory Graft Versus Host Disease

Interventions

CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)BIOLOGICAL

Subjects will receive seven planned doses of CK0802 on study day +1, +3 (+/-1 day), +5 (+/-1 day), +7 (+/- 2 day), +14 (+/- 3 days), +21 (+/-3 days) and +28 (+/-3 days). A total of 7 doses will be administered. If Day 29 assessment shows PR or MR, then 4 additional weekly infusion of CK0802 Tregs can be administered (study days: 35 (+/- 2 day), 42 (+/- 2 day), 49 (+/- 2 day), and 55(+/- 2 day)), for a total of 11 infusions

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Age ≥12 years old (first 3 subjects will be ≥ 18 years) * 2\. Grade 2-4 acute GVHD (aGVHD) at baseline * 3\. No other prior aGVHD treatment * 4\. Steroid Refractory * Progressed after 3 days of treatment with 2 mg/kg methylprednisolone (MPE) * No improvement after 7 days of treatment with 2 mg/kg MPE * Progressed to a new organ after treatment with 1 mg/kg MPE for skin or upper gastrointestinal (UGI) aGVHD * Progressed from nadir during or after a steroid taper * 5\. Female subjects of childbearing potential (FPCP) must have a negative urine or serum pregnancy test. * 6\. Agreed to abide by all protocol required procedures including study-related assessments, visits and long term follow up. * 7\. Willing and able to provide written informed consent. * 8\. Signed informed consent Exclusion Criteria: * 1\. 30 days prior treatment with any other investigational agent after allogeneic HSCT. * 2\. Known HIV seropositivity. * 3\. Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy. The Protocol PI is the final arbiter of eligibility. * 4\. Subjects with uncontrolled inter-current illness that in the opinion of the investigator would place the subject at greater risk of severe toxicity and/or impair the activity of CK0802. * 5\. Subjects who are pregnant or breastfeeding.

Outcomes

Primary Outcomes

Phase 1b

Dose limiting toxicities of CK0802 in SR GVHD as assessed by the incidence and severity of AE and SAEs determined by the NCI-CTCAE Version 6.0. Non-Hematologic: Any ≥ Grade 3 non-hematologic AE as per CTCAE v6.0 Hematologic: Any new or worsened Grade 4 neutropenia, thrombocytopenia, or anemia compared with baseline that persists for \>7 days despite supportive care and is not clearly and incontrovertibly attributable to the underlying disease or another extraneous cause. Death: Death within 28 days that is not clearly and incontrovertibly attributable to the underlying disease or another extraneous cause

Time frame: Day +29

Phase 2a

Overall Response (OR) at day +29. Overall response (OR) will include complete response (CR) and partial response (PR). Response to be determined from the maximum acute GVHD stage and grade in each organ. Complete Response (CR): Stage 0 in all organs (skin, liver, and GI tract) and no intervening additional therapy Partial Response (PR): Improvement of at least 1 stage in 1 or more organs without progression in other organs, and no intervening additional therapy Overall Response (OR): Includes both CR and PR Very Good PR (VGPR): Improvement by at least one stage in one or more organs and * Skin: No rash, or bullae, and residual erythematous rash involving \<25% of the body surface * Liver: Total serum bilirubin concentration of \<2 mg/dL or \<25% of baseline at enrollment * Gut: Tolerating food or enteral feeding, predominantly formed stools, no overt GI bleeding or abdominal cramping, no more than occasional nausea or vomiting * No intervening additional therapy

Time frame: D +29

Central Contacts

Clinical Trial Specialist

CONTACT

8002178247 contact@cellenkosinc.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.